^
Association details:
| Biomarker: | CXCR6 expression + HAVCR2 expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1672 - Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
Published date:
03/10/2021
Excerpt:
Metastatic melanoma patients received weight based pembrolizumab...There was significantly higher frequency of co-expression of CXCR6 and TIM3 on CD4+ T cells for PD (mean 21.5% CI 14.9% - 26.06%) compared to CR (mean 12.2% CI 9.40% - 14.99%) (p=0.003) and PR (mean 9.9% CI 7.76% - 12.05%) (p=0.0001). There was also significantly higher frequency of co-expression of CXCR6 and TIM3 on CD8+ T cells for PD (mean 32.59% CI 25.76% - 39.43%) compared to PR (mean 21.9% CI 18.22% - 25.56%) (p=0.032).
